Baiji Shenzhou zebutinib new indications approved by FDA
Baiji Shenzhou announced that baiyueze ®（ BRUKINSA ®， Zebutinib) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with macroglobulinemia (WM). This is bayeuser ® The second approval obtained by FDA is also the third approval of Fahrenheit macroglobulinemia worldwide.
This text is a result of machine translation.
Related companies：
Briefing Jun 10, 2022 09:48 PM
Singaporean Prime Minister Lee Hsien Loong meets with weifenghe
In-depth
Briefing Jun 10, 2022 07:17 PM
Baiji Shenzhou PD-1 monoclonal antibody baizean ® The ninth indication was obtained and the first-line treatment for nasopharyngeal carcinoma was approved
Briefing Apr 28, 2022 09:59 AM
A new breakthrough in the first-line treatment of advanced esophageal cancer: PD-1 monoclonal antibody baizean ® Global phase 3 clinical trials reached the primary end point
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 18, 2022 06:30 PM
Briefing Mar 11, 2022 10:59 AM
· Financials
Baiji China: the tentative list is a normal step and will not affect the listing of the company on NASDAQ
Briefing Feb 25, 2022 08:48 PM
Ministry of agriculture and rural areas: implement the ten-year fishing ban on the Yangtze River in 2022 and promote the conservation of aquatic biological resources
Briefing Feb 15, 2022 06:19 AM
· Automotive
Hillhouse Q4 position: increased holdings of ideal automobile and Xiaopeng automobile sea, and ideal automobile rushed into the top ten
Briefing Jan 31, 2022 10:29 AM
· Healthcare
Hong Kong Pharmaceutical stocks generally rose, with Cinda biology up nearly 6%
Briefing Jan 05, 2022 11:24 AM
· Healthcare
54% off! Pamipali, the first PARP inhibitor approved for the treatment of platinum sensitive and platinum resistant recurrent ovarian cancer, was included in Medicare
See more
Read next
Insight
In-depth
Consumer Staples · Analysis
Chinese Cuisine Brand YGF Malatang Ventures into Brazil
Apr 23, 2024 02:21 PM